Clinical path for mFOLFOX6 describing criteria for reduction and suspension of drugs
Okada, N.; Ishibashi, K.; Ohsawa, T.; Sobajima, J.; Kuwabara, K.; Ishiguro, T.; Amano, K.; Hatano, S.; Hokama, N.; Tajima, Y.; Ishii, M.; Yokoyama, Y.; Yamamoto, A.; Kumamoto, K.; Haga, N.; Ishida, H.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(12): 2588-2590
2010
ISSN/ISBN: 0385-0684 PMID: 21224648 Document Number: 643943
Clinical path for executing mFOLFOX6 in an outpatient chemotherapy room was settled on for the aim of standardization and common information with medical staffs about mFOLFOX6. The feature of this clinical path is described doses of drugs, results of laboratory examination, criteria for deciding adverse effects, common adverse effects and management, criteria for reduction and suspension of oxaliplatin and 5-fluorouracil. Patients before induction of the clinical path were compared with patients after that about relative dose intensity (RDI), reasons why treatments were suspended and progression-free survival (PFS). Fifty eight patients after induction were significantly higher RDI of oxaliplatin than 108 patients before induction (p=0.04). There were no significant differences about a frequency of suspension due to adverse effects (p=0.18) and PFS (p=0.74). The clinical path that we settled on was considered useful not only for common information with medical staffs but also for standardization.